J. F. Pérez

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

UNLABELLED PARP inhibitors are active in tumors with defects in DNA homologous recombination (HR) due to BRCA1/2 mutations. The phosphoinositide 3-kinase (PI3K) signaling pathway preserves HR steady state. We hypothesized that in BRCA-proficient triple-negative breast cancer (TNBC), PI3K inhibition would result in HR impairment and subsequent sensitization to PARP inhibitors. We show in TNBC cells that PI3K inhibition leads to DNA damage, downregulation of BRCA1/2, gain in poly-ADP-ribosylation, and subsequent sensitization to PARP inhibition. In TNBC patient-derived primary tumor xenografts, dual PI3K and PARP inhibition with BKM120 and olaparib reduced the growth of tumors displaying BRCA1/2 downregulation following PI3K inhibition. PI3K-mediated BRCA downregulation was accompanied by extracellular signal-regulated kinase (ERK) phosphorylation. Overexpression of an active form of MEK1 resulted in ERK activation and downregulation of BRCA1, whereas the MEK inhibitor AZD6244 increased BRCA1/2 expression and reversed the effects of MEK1. We subsequently identified that the ETS1 transcription factor was involved in the ERK-dependent BRCA1/2 downregulation and that knockdown of ETS1 led to increased BRCA1/2 expression, limiting the sensitivity to combined BKM120 and olaparib in 3-dimensional culture. SIGNIFICANCE Treatment options are limited for patients with TNBCs. PARP inhibitors have clinical activity restricted to a small subgroup of patients with BRCA mutations. Here, we show that PI3K blockade results in HR impairment and sensitization to PARP inhibition in TNBCs without BRCA mutations, providing a rationale to combine PI3K and PARP inhibitors in this indication. Our findings could greatly expand the number of patients with breast cancer that would benefit from therapy with PARP inhibitors. On the basis of our findings, a clinical trial with BKM120 and olaparib is being initiated in patients with TNBCs.

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.

Clinical benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified breast cancer remain limited by primary or acquired resistance. To identify potential mechanisms of resistance, we established trastuzumab-resistant HER2 amplified breast cancer cells by chronic exposure to trastuzumab treatment. Genomewide copy-number variation analyses of the resistant cells compared with parental cells revealed a focal amplification of genomic DNA containing the cyclin E gene. In a cohort of 34 HER2+ patients treated with trastuzumab-based therapy, we found that cyclin E amplification/overexpression was associated with a worse clinical benefit (33.3% compared with 87.5%, P < 0.02) and a lower progression-free survival (6 mo vs. 14 mo, P < 0.002) compared with nonoverexpressing cyclin E tumors. To dissect the potential role of cyclin E in trastuzumab resistance, we studied the effects of cyclin E overexpression and cyclin E suppression. Cyclin E overexpression resulted in resistance to trastuzumab both in vitro and in vivo. Inhibition of cyclin E activity in cyclin E-amplified trastuzumab resistant clones, either by knockdown of cyclin E expression or treatment with cyclin-dependent kinase 2 (CDK2) inhibitors, led to a dramatic decrease in proliferation and enhanced apoptosis. In vivo, CDK2 inhibition significantly reduced tumor growth of trastuzumab-resistant xenografts. Our findings point to a causative role for cyclin E overexpression and the consequent increase in CDK2 activity in trastuzumab resistance and suggest that treatment with CDK2 inhibitors may be a valid strategy in patients with breast tumors with HER2 and cyclin E coamplification/overexpression.

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

Purpose: The PI3K/Akt/mTOR pathway is an attractive target in HER2-positive breast cancer that is refractory to anti-HER2 therapy. The hypothesis is that the suppression of this pathway results in sensitization to anti-HER2 agents. However, this combinatorial strategy has not been comprehensively tested in models of trastuzumab and lapatinib resistance. Experimental Design: We analyzed in vitro cell viability and induction of apoptosis in five different cell lines resistant to trastuzumab and lapatinib. Inhibition of HER2/HER3 phosphorylation, PI3K/Akt/mTOR, and extracellular signal-regulated kinase (ERK) signaling pathways was evaluated by Western blotting. Tumor growth inhibition after treatment with lapatinib, INK-128, or the combination of both agents was evaluated in three different animal models: two cell-based xenograft models refractory to both trastuzumab and lapatinib and a xenograft derived from a patient who relapsed on trastuzumab-based therapy. Results: The addition of lapatinib to INK-128 prevented both HER2 and HER3 phosphorylation induced by INK-128, resulting in inhibition of both PI3K/Akt/mTOR and ERK pathways. This dual blockade produced synergistic induction of cell death in five different HER2-positive cell lines resistant to trastuzumab and lapatinib. In vivo, both cell line–based and patient-derived xenografts showed exquisite sensitivity to the antitumor activity of the combination of lapatinib and INK-128, which resulted in durable tumor shrinkage and exhibited no signs of toxicity in these models. Conclusions: The simultaneous blockade of both PI3K/Akt/mTOR and ERK pathways obtained by combining lapatinib with INK-128 acts synergistically in inducing cell death and tumor regression in breast cancer models refractory to anti-HER2 therapy. Clin Cancer Res; 18(9); 2603–12. ©2012 AACR.

Determination of rumen microbial-nitrogen production in sheep : a comparison of urinary purine excretion with methods using 15N and purine bases as markers of microbial-nitrogen entering the duodenum

The present study compares estimates of rumen microbial-N production derived from duodenal flow measurements (15N and purine bases) with those from measurements of the urinary excretion of purine derivatives. Four Rasa Aragonesa ewes fitted with simple cannulas in the rumen and proximal duodenum were used. Four diets consisting of 550 g lucerne (Medicago sativa) hay/d as sole feed or supplemented with 220, 400 and 550 g rolled barley grain/d were given in a 4 x 4 random factorial arrangement. Duodenal digesta flows were determined by the dual-phase marker technique during continuous intraruminal infusions of Co-EDTA and Yb-acetate. Microbial contribution to the non-NH3 N (NAN) flow was estimated from 15N enrichment and purines: N ratio in duodenal digesta and bacterial fractions isolated from the rumen content. Whole tract organic matter (OM) digestibility and duodenal flow of OM and NAN increased (P < 0.001) with the level of barley supplementation. Digestible OM intake ranged from 19.0 to 42.7 g/kg metabolic weight (W0.75) and the duodenal flow of purine bases and the urinary excretion of allantoin increased linearly (P < 0.001) from minimum values of 7.47 (SD 1.524) and 4.65 (SD 0.705) mmol/d respectively on the basal diet to 18.20 (SD 1.751) and 11.62 (SD 0.214) mmol/d on the 400 g barley diet; a further increase in barley supplementation decreased both variables (13.50 (SD 2.334) and 8.77 (SD 0.617) mmol/d respectively). Urinary excretion of uric acid and hypoxanthine showed a slight but significant increase (P < 0.05) over all levels of barley. Molar recoveries of duodenal purine bases as purine derivatives or allantoin in the urine were 0.78 (SD 0.156) and 0.65 (SD 0.130) respectively. The increase on barley supplementation significantly augmented microbial-N, but large differences between microbial markers employed were observed. Mean values of microbial-N estimated from the duodenal purine bases or urinary allantoin excretion were on average 18 and 29% lower than those measured by 15N.

Effect of dietary level of protein and fiber on the productive performance and health status of piglets.

To study the interaction between the levels of protein and fiber on the productive performance and health status of piglets, ninety-six 35-d-old piglets (9.11 +/- 0.60 kg of BW) were placed in 32 pens of 3 animals each and allotted to 4 dietary treatments for 21 d. The 4 diets were based on rice, dairy products, and soybean meal in a 2 x 2 factorial arrangement of treatments, with 2 levels of CP (15.4 vs. 19.4%, as-fed basis) and 2 levels of dietary fiber [DF; low fiber (LF) 5.3% NDF and high fiber (HF) 7.15% NDF, as-fed basis]. The HF diet was developed by supplementing the basal diet with 40 g/kg of wheat bran and 20 g/kg of sugar beet pulp. Animal performance was obtained weekly with samples of feces collected for microbiology on the first and the last experimental day and scored from 1 (liquid) to 4 (hard). On the last day, 1 pig from each pen was sampled for blood analyses of the acute-phase protein, major acute-phase protein of pigs (PigMap) and subsequently killed to register the digestive tract weight (including contents) and colon histology. Pigs fed the HF diets had greater ADG (390 vs. 457 g; P < or = 0.001) and large intestine weight (4.4 vs. 5.4% of BW; P < or = 0.05). This coincided with a greater (P < or = 0.05) short-chain fatty acid concentration (especially of acetic and butyric acids), a decrease in Escherichia coli counts (7.77 vs. 6.86 log of cfu/g of feces, P < or = 0.05), and an increase in the ratio of lactobacilli:enterobacteria (0.76 vs. 1.37, P < or = 0.05). However, CP level did not modify the productive performance, but 20% CP increased P < or = 0.05) the relative weight (% of BW) of the small (6.5 vs. 7.7) and large intestine (3.8 vs. 4.3). In the large bowel, the 20% CP diet increased the numbers of goblet cells (4.6 vs. 5.4/100 microm; P < or = 0.05) and reduced the numbers of intraepithelial lymphocytes (1.8 vs. 1.3/100 microm; P < or = 0.05). In relation to health status, increasing DF was dependent of the dietary CP content. Supplementing the 16% CP diet with DF reduced the fecal score and increased the antibiotics interventions, whereas the opposite was the case in the 20% CP diet. Pigs fed the 20% CP diet showed decreased (P < or = 0.05) PigMap concentrations than pigs fed 16% CP diets. As a whole, CP showed major effects on the gastrointestinal weight and gut barrier integrity, whereas DF increased the productive performance and promoted major changes in the microbial colonization and fermentation variables.

Effects of dietary AflaDetox on performance, serum biochemistry, histopathological changes, and aflatoxin residues in broilers exposed to aflatoxin B1

The aim of this study was to evaluate the ability of AflaDetox (Adiveter, Agro-Reus, Reus, Tarragona, Spain) in counteracting the deleterious effects of aflatoxin B(1) (AFB(1)) in broiler chicks. A total of 120 Ross 308 one-day-old male broiler chicks were assigned to 8 treatments for 42 d. The experiment had a 2 x 4 factorial arrangement of treatments involving 0 and 1 mg of AFB(1)/kg feed and 0, 1, 2, and 5 g of AflaDetox/kg feed. Chicks were fed on the ground during the first 7 d and in cages (3 chicks/cage; 5 cages/treatment) from 7 to 42 d. Growth performance was measured from d 7 to 42 and whole-tract digestibility of gross energy and protein on d 40 to 41. Serum biochemical parameters, organ weights, histopathological examination of liver, and AFB(1) residues in liver and breast muscle tissues were determined on d 42. Aflatoxin B(1) significantly decreased the BW gain, feed intake, and impaired feed conversion rate (P < 0.05). The addition of AflaDetox in the contaminated diets significantly diminished the inhibitory effects of dietary AFB(1) (P < 0.05) on the growth performance with no differences compared to the control diet. Feeding AFB(1) alone decreased serum protein concentration, increased the serum activity of alkaline phosphatase, and caused significant increases in the relative weights of livers. Treatment with AflaDetox significantly alleviated the negative effects of AFB(1) on these parameters (P < 0.05) with no effect on uncontaminated diets. Liver tissue of broilers receiving AFB(1) alone had perilobular inflammation and vacuolar degeneration of hepatocytes as compared with the tissue from the control group (P < 0.05). Residues of AFB(1) were detected in the liver tissues of broilers fed on the AFB(1) diet (0.166 microg/kg). Supplementation of AflaDetox reduced the incidence and severity of the hepatic histopathology changes associated with aflatoxicosis and the amount of AFB(1) residue in liver. In conclusion, our results showed that addition of AflaDetox may reduce the adverse effects produced by the presence of AFB(1) in broiler chickens diets.

Effect of Acidified Feed on the Prevalence of Salmonella in Market-age Pigs

Two trials were carried out to determine the effect of feed acidification upon Salmonella carriage in market‐age pigs. In the first trial, the administration for the last 14 weeks of the fattening period of a commercial pelleted feed added with 0.6% lactic acid plus 0.6% formic acid (Lac‐Formic‐1.2) was compared to an unacidified standard diet (STD). A second experiment was carried out in two herds of growing pigs (Herd I, 3000 pigs; Herd II, 900 pigs) in which three different diets were assayed during the last 8–9 weeks of the fattening period: a diet containing 0.8% formic acid (Formic‐0.8), a diet containing 0.4% lactic acid plus 0.4% formic acid (Lac‐Formic‐0.8) and a STD. In the first experiment, serological evolution of the infection was examined by ELISA and microbiological cultures (rectal samples and mesenteric lymph nodes) were also done. Feed intake by pen and the individual weight of the animals were also measured. In the second trial, blood, rectal samples and mesenteric lymph nodes were collected at slaughter in both herds (30 pigs per experimental group). In the first experiment, the acidified diet (Lac‐Formic‐1.2) reduced Salmonella carriers in mesenteric lymph nodes (Fisher’s exact P < 0.01). In the second trial, Lac‐Formic‐0.8 diet significantly reduced Salmonella seroprevalence compared to the STD (P = 0.001) in both herds. Also Lac‐Formic‐0.8 and Formic‐0.8 diets in Herd II showed a lower faecal excretion and Salmonella carriage in mesenteric lymph nodes than the STD (P < 0.05). Our results suggest that the administration of a combination of lactic and formic acids at the levels used in this study could be used to reduce Salmonella prevalence in finishing pigs.

Efficacy of a New Ochratoxin-Binding Agent (OcraTox) to Counteract the Deleterious Effects of Ochratoxin A in Laying Hens

An experiment was conducted to evaluate the efficacy of a new ochratoxin-binding agent (Ocra-Tox, 5 g/kg of feed) in offsetting the toxic effects of ochratoxin A (OTA, 2 mg/kg of feed) in laying hen diets. Performance, serum biochemistry, OTA residue in the liver and eggs, and egg quality parameters were evaluated. Twenty-eight Hisex Brown laying hens, 47 wk of age, were allocated to 1 of 4 experimental treatments for 3 wk: control, OTA (containing 2 mg of OTA/kg of feed), OcraTox (containing 5 g of OcraTox/kg of feed), and OTA + OcraTox (containing 2 mg of OTA and 5 g of OcraTox/kg of feed). Laying hens fed OcraTox showed results similar to the control hens (P > 0.05). The OTA diet significantly (P < 0.05) reduced daily feed consumption, egg mass production, and serum triglyceride concentrations, and increased the relative liver weight, the serum activity of alkaline phosphatase, and the serum concentration of uric acid as compared with the control diet. Addition of OcraTox to the contaminated diet alleviated (P < 0.05) the negative effects resulting from OTA, reaching values not significantly different from the control diet for most of the parameters except the relative weight of the liver. Birds fed the OTA treatment showed a greater content of OTA in the liver (15.1 microg/kg) than those fed the control diet (<0.05 microg/kg). Supplementing the contaminated diet with OcraTox (OTA + OcraTox) reduced the values to 12.0 microg/kg. Residues of OTA were not detected above our detection limit (0.05 microg/kg) in any of the analyzed eggs. In conclusion, our results indicated that addition of OcraTox can counteract the deleterious effects caused by OTA in laying hens.

Comparative digestibility and lipogenic activity in Landrace and Iberian finishing pigs fed ad libitum corn- and corn–sorghum–acorn-based diets

Forty-eight finishing castrated male pigs (24 Iberian and 24 Landrace; 88.4 kg LW) were fed two diets differing in main carbohydrates sources, corn- (Diet C) or corn–sorghum–acorn (Diet A). After 28 days of experimental period, 24 animals (six per treatment) were slaughtered and digesta and carcass sampled to study digestion and lipogenesis activity. Iberian pigs showed a higher voluntary feed intake than Landrace pigs (3.5 vs. 2.7 kg/day; P<0.01), but no significant differences in the daily weight gain. Between diets, no significant differences were observed in the production data. However, the whole-tract digestibility was significantly lower with Diet A than with Diet C for OM, CP and monosaccharides. Whole-tract apparent digestibility of Iberian pigs was also significantly lower than of Landrace (P<0.01), especially for those animals fed Diet A. As a result of feed intake and digestibility coefficients, Iberian pigs showed a higher intake of digestible OM (2910 g/day) than Landrace (2310 g/day), which was associated with higher (P<0.05) backfat thickness, muscle fat content and lipogenic enzyme activities. Lipogenesis was not broadly influenced by the dietary treatments, except a significant decrease in the intermuscular adipose tissue with diet A. We conclude that digestibility and lipogenic enzyme activities were markedly influenced by the animal breed and to a lesser extent by the diet.

Ochratoxins in Feed, a Risk for Animal and Human Health: Control Strategies

Ochratoxin A (OTA) has been shown to be a potent nephrotoxic, hepatotoxic, and teratogenic compound. In farm animals, the intake of feed contaminated with OTA affects animal health and productivity, and may result in the presence of OTA in the animal products. Strategies for the control of OTA in food products require early identification and elimination of contaminated commodities from the food chain. However, current analytical protocols may fail to identify contaminated products, especially in animal feed. The present paper discusses the impact of OTA on human and animal health, with special emphasis on the potential risks of OTA residue in animal products, and control strategies applied in the feed industry.